GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials. Gupta P, Pozzilli V, De Giovanni A, Sapio E, Motolese F, Capone F, Pozzilli P J Neuroendocrinol. 2026 Aug; 38(8):e70246. PMID: 42580680. Abstract CommentRecommendBookmarkWatch
